AzTrials
AzTrials

PeriodontitisNCT06135532

Chemerin, Fetuin-A, IL-34 and IL-13 Levels in Diabetic Periodontitis Patients

A study testing Non-Surgical Periodontal Treatment in people with Periodontitis and Diabetes Mellitus, Type 2, run by Marmara University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The present study aimed to assess the effect of non-surgical periodontal treatment on serum and salivary chemerin, fetuin-A, IL-34 and IL-13 levels in periodontitis with and without diabetes mellitus (DM) type 2. Read more about this study

Who is it for?
Ages 23 to 69 yearsHealthy volunteers can take part
Conditions the study is for
Periodontitis, Diabetes Mellitus, Type 2
What is being tested?
Non-Surgical Periodontal Treatment
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
110 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Oct 2018to 21 Feb 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 23 to 69 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • non-smoker individuals
  • having ≥20 teeth present (except third molars)
  • individuals with non-periodontitis (healthy or gingivitis) and stage III grade C periodontitis diagnoses
  • diagnosed at least one year ago as having T2DM and treated with oral anti-diabetics and/or insulin, no major diabetic complications (retinopathy, nephropathy, neuropathy)

Who cannot join

  • having any diagnosed medical disorders other than diabetes mellitus, such as cardiovascular diseases, rheumatoid arthritis, immunological and mucocutaneous diseases
  • usage of antibiotics, non-steroidal anti-inflammatory drugs, and immunosuppressive agents within the past 6 months.
  • periodontal treatment within the preceding 6 months.
  • pregnant/ lactating/ postmenopausal females.
  • current orthodontic treatment.

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Marmara University

    Istanbul, 34854

Other trials in Turkey (Türkiye)

About this study

Official title: Effect of Non-surgical Periodontal Treatment on Chemerin, Fetuin-A, IL-34 and IL-13 Levels in Type 2 Diabetic Periodontitis Patients

The present study aimed to assess the effect of non-surgical periodontal treatment on serum and salivary chemerin, fetuin-A, IL-34 and IL-13 levels in periodontitis with and without diabetes mellitus (DM) type 2. 22 non-periodontitis, 22 non-periodontitis with DM, 22 Stage III/IV Grade C periodontitis, 22 tage III/IV Grade C periodontitis with well-controlled DM and 22 tage III/IV Grade C periodontitis with poorly-controlled DM patients were enrolled. At baseline, serum and saliva samples were collected, and the whole mouth clinical periodontal parameters were recorded from all subjects. Periodontitis patients received non-surgical periodontal therapy. Clinical parameters were re-measured, and samples were re-collected 1 and 3 months after therapy from periodontitis patients. Serum and salivary protein levels were analyzed by ELISA. Data were analyzed using appropriate statistical tests.

Read the detailed description

Type 2 diabetes (T2DM) increases the risk for severe periodontal disease by three times, making it a risk factor for the progression of periodontitis. Periodontitis works as a focus of local infection and a source of low-grade chronic inflammation. Periodontal therapy primarily targets the microbial component of the disease by mechanical debridement of tooth surfaces.

Chemerin, an adipose tissue-specific adipokine, influences the glucose pathway, lipid metabolism, inflammation levels, chemotaxis of immature dendritic cells, and integration of macrophage-phagocytic activity to extracellular matrix proteins and adhesion molecules. Fetuin-A impedes insulin receptor tyrosine kinase, thus affiliated with insulin resistance, metabolic syndrome, and an increased risk for type 2 diabetes mellitus. Interleukin (IL)-34 modulates myeloid cell differentiation, proliferation, and survival. Depending on the microenvironment, IL-34 can transform circulating monocytes into specific non-resident macrophages with a "pro-inflammatory" M1 phenotype or an "anti-inflammatory" M2 phenotype. IL-13 inhibits the release of inflammatory cytokines, such as IL-1, IL-6, and TNF-α, from monocytes and macrophages.

This study is the first controlled clinical study that examines the levels of chemerin, fetuin-A, IL-34, and IL-13 in saliva and serum in periodontitis with and without T2DM (well-controlled and poorly-controlled T2DM) and evaluates the situation before and after the treatment. The first hypothesis of this study is that in periodontitis groups, chemerin and IL-34 levels will be high in saliva and serum, and IL-13 and fetuin-A levels will be low in contrast to the non-periodontitis groups. The second hypothesis of this study is that in T2DM groups, fetuin-A and chemerin levels will be high compared to participants without T2DM. The third hypothesis of this study, after periodontal treatment, chemein and IL-34 levels will decrease, and IL-13 and fetuin-A will increase in saliva and serum. Based on these hypotheses, the study aims to compare the levels of chemerin, fetuin-A, IL-34, and IL-13 in saliva and serum of nonperiodontitis controls (NP), NP with T2DM (DM.NP), periodontitis (P), P with well-controlled T2DM (WDM.P) and P with poorly-controlled T2DM (PDM.P) subjects and to evaluate the effect of periodontal treatment.

A total of 110 participants, 22 NP, 22 DM.NP, 22 P, 22 WDM.P, and 22 PDM.P were included in this study. The whole mouth clinical periodontal examination included measurement of probing depth (PPD), clinical attachment level (CAL), presence of bleeding on probing (BOP), gingival index (GI), and plaque index (PI) at 6 sites per tooth, except the third molars. The presence and type of the alveolar bone loss were assessed on the digital panoramic radiograph in each participant, which was supplemented with periapical radiographs if necessary.

The periodontal status of each patient was evaluated by a single calibrated periodontist with a manual probe. The diagnosis of periodontitis or periodontally health was determined according to the 2017 World Workshop on Classification of Periodontal and Peri-Implant Diseases and Conditions. NP individuals (healthy and gingivitis) (n=22) in the control group had no sites with PD >3 mm and CAL >2 mm and no radiographic evidence of alveolar bone loss. NP group also exhibited no history of periodontitis. The periodontitis stage III/IV patients had a minimum of three teeth apart from the first molars and incisors showing CAL ≥5 mm and PD ≥6 mm. Radiographic bone loss extending from coronal to middle third or beyond. Bone loss %/age was higher than 1.0.

The diagnosis of patients with T2DM was based on the criteria given by the World Health Organization. Both well-controlled and poorly-controlled diabetic patients, diagnosed at least one year ago as having T2DM and treated with oral anti-diabetics and/or insulin, no major diabetic complications (retinopathy, nephropathy, neuropathy), were included.

Treatment

The recruited periodontitis patients received conventional quadrant scaling and root planning (SRP) under local anesthesia in a total of 4 sessions in four weeks. SRP was performed by the same periodontist using ultrasonic inserts and manual periodontal curettes. Re-evaluations were performed at 1 and 3 months following the completion of the SRP. No periodontal intervention was carried out in the non-periodontitis controls.

Saliva and serum Sampling A total of 5 mL of unstimulated whole saliva was collected by passive drool method between 9:00 and 10:00 a.m. The participants were advised to avoid food consumption for three hours before sample collection. The participants were seated upright, and saliva was collected over 5 minutes with instructions to pool saliva in the floor of the mouth and passively drool it into a sterile glass beaker. Then, saliva samples are immediately transferred to a 2 mL polypropylene tube and stored at -80°C. A total of 10,5 mL of blood was collected from the antecubital fossa by the venepuncture method. Serum was isolated from the blood by centrifuging at 4000 rpm for 12 minutes, followed by its rapid transfer to a sterile polypropylene tube and storage at -80°C.

Biomarker Immunoassays Saliva and serum samples were thawed on ice. The saliva samples were centrifuged at 5000 rpm for 15 minutes at room temperature, and supernatants were immediately used for assays. Using commercial kits, serum and salivary samples of chemerin, fetuin-A, IL-34, and IL-13 were measured by ELISA.

Statistical Analysis Shapiro Wilk's normality test was applied to determine the clinical and biochemical data distribution. Nonparametric tests were used because the variables did not follow a normal distribution. The gender distributions among groups were analyzed using the Chi-Square test. Multiple comparisons of the clinical and biochemical parameters were analyzed using the Kruskal-Wallis; if significance occurred, the Bonferroni-adjusted Mann-Whitney U test was applied for paired comparisons. Intragroup comparisons were performed using the Wilcoxon signed-rank test. The correlations among clinical and biochemical parameters at baseline were performed using Spearman's rank correlation analysis. Multinomial logistic regression was used to determine associations between periodontitis groups and biochemical parameters. The level of significance was set at P < 0.05.

Being tested
Non-Surgical Periodontal Treatment
Keywords
periodontitis, Diabetes mellitus, periodontal therapy
Medical subject headings
Periodontitis, Diabetes Mellitus, Type 2, Diabetes Mellitus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Non-Surgical Periodontal TreatmentProcedure or surgery

    Nonsurgical periodontal therapy primarily aims to control microbial periodontal infection by removing bacterial biofilm, calculus, and toxins from periodontally involved root surfaces. Performing a thorough periodontal debridement under local anesthesia will stop disease progression and improve active disease's clinical signs and symptoms.

Study groups in NCT06135532
Study groupRoleWhat they receive
Non-PeriodontitisNo interventionOnly received instructions in proper self-performed plaque control measures, including brushing and interproximal cleaning with dental floss and interdental brushes.
Non-Peridontitis with T2DMNo interventionOnly received instructions in proper self-performed plaque control measures, including brushing and interproximal cleaning with dental floss and interdental brushes.
PeriodontitisActive comparatorThe patients received instructions in proper self-performed plaque control measures, including brushing and interproximal cleaning with dental floss and interdental brushes. The patients underwent quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment was completed in a total of 4 sessions in four weeks.
Receives: Procedure: Non-Surgical Periodontal Treatment
Periodontitis with well-controlled T2DMActive comparatorThe patients received instructions in proper self-performed plaque control measures, including brushing and interproximal cleaning with dental floss and interdental brushes. The patients underwent quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment was completed in a total of 4 sessions in four weeks.
Receives: Procedure: Non-Surgical Periodontal Treatment
Periodontitis with poorly-controlled T2DMActive comparatorThe patients received instructions in proper self-performed plaque control measures, including brushing and interproximal cleaning with dental floss and interdental brushes. The patients underwent quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment was completed in a total of 4 sessions in four weeks.
Receives: Procedure: Non-Surgical Periodontal Treatment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. salivary chemerin level (ng/ml)

    change in salivary chemerin levels

    Measured: baseline to 3 months after non-surgical

  2. salivary fetuin-A level (ng/ml)

    change in salivary fetuin-A levels

    Measured: baseline to 3 months after non-surgical

  3. salivary IL-34 level (pg/ml)

    change in salivary IL-34 levels

    Measured: baseline to 3 months after non-surgical

  4. salivary IL-13 level (pg/ml)

    change in salivary IL-13 levels

    Measured: baseline to 3 months after non-surgical

Secondary outcomes (4)
  1. serum chemerin level (ng/ml)

    change in serum chemerin levels

    Measured: baseline to 3 months after non-surgical

  2. serum fetuin-A level (ng/ml)

    change in serum fetuin-A levels

    Measured: baseline to 3 months after non-surgical

  3. serum IL-34 level (pg/ml)

    change in serum IL-34 levels

    Measured: baseline to 3 months after non-surgical

  4. serum IL-13 level (pg/ml)

    change in serum IL-13 levels

    Measured: baseline to 3 months after non-surgical

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Nov 2023
  2. Study start1 Oct 2018
  3. Primary completion21 Feb 2020
  4. Study completion21 Feb 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
110 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06135532
Sponsor's protocol ID
SAG-A-080519-0172
Status last verified
Nov 2023
First submitted
11 Nov 2023
Last updated
18 Nov 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Gorgulu NG, Gungormek HS, Kalkan Y, Dogan B. Evaluation of chemerin, fetuin-A, interleukin-34, and interleukin-13 levels following periodontal treatment in diabetes mellitus. Clin Oral Investig. 2025 Sep 11;29(10):448. doi: 10.1007/s00784-025-06539-3.

    PubMed 40932532

Questions about this trial

What is this clinical trial studying?

A study testing Non-Surgical Periodontal Treatment in people with Periodontitis and Diabetes Mellitus, Type 2, run by Marmara University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

salivary chemerin level (ng/ml) (time frame: baseline to 3 months after non-surgical). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06135532, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in